Premature Ejaculation in the United Kingdom: Variation and Gaps in Contemporary Urological Practice

ABSTRACT To present the first nationally disseminated assessment of UK urologists’ perceptions and management of Premature Ejaculation (PE), focusing on alignment with consensus recommendations. A cross‐sectional study was conducted, using anonymised electronic questionnaires distributed to UK urology clinicians following the British Association of Urological Surgeons Annual Scientific Meeting in 2025. Data collected included clinician demographics, clinical exposure to PE, diagnostic criteria used, and treatment strategies. Descriptive statistics were applied. Sixty‐six responses were analysed. Half of respondents were general urologists, and clinical exposure to PE was limited; 37.9% reported no PE cases in the preceding 3 months. Diagnostic approaches varied; patient‐reported concern was most used (49.2%), followed by International Society for Sexual Medicine (33.9%) and American Urological Association/Sexual Medicine Society of North America (12.3%) definitions. Objective assessment of intravaginal ejaculatory latency time was inconsistent; 10.9% used formal timing strategies. Dapoxetine was the commonest prescribed therapy (34.1%), followed by topical anaesthetics (26.8%) and phosphodiesterase‐5 inhibitors (16.7%). 33.3% of respondents reported at least one patient requesting invasive treatment; however, invasive procedures were rarely considered, with 96.9% reporting no referral. Barriers included insufficient evidence, and no guideline endorsement; 98.5% of respondents felt current guidelines do not reflect real world challenges in managing PE. UK urologists demonstrate substantial variability in PE diagnosis and management, with heterogeneous alignment to consensus‐based frameworks. These findings highlight implementation gaps and underscore the need for clearer national guidance given the prevalence of PE.